| Bone marrow transplantation for Behçet’s disease: a case report and systematic review of the literature T Soysal, A Salihoğlu, SN Esatoğlu, E Gültürk, AE Eşkazan, G Hatemi, ... Rheumatology 53 (6), 1136-1141, 2014 | 54 | 2014 |
| Midostaurin in FLT3-Mutated Acute Myeloid Leukemia. RM Stone, RA Larson, H Doehner The New England journal of medicine 377 (19), 1903-1903, 2017 | 50 | 2017 |
| Dasatinib‐induced pulmonary arterial hypertension N Özgür Yurttaş, AE Eşkazan British Journal of Clinical Pharmacology 84 (5), 835-845, 2018 | 45 | 2018 |
| Bortezomib therapy in patients with relapsed/refractory acquired thrombotic thrombocytopenic purpura AE Eskazan Annals of hematology 95 (11), 1751-1756, 2016 | 45 | 2016 |
| COVID‐19 presenting with immune thrombocytopenia: a case report and review of the literature A Murt, AE Eskazan, U Yılmaz, T Ozkan, MC Ar Journal of medical virology, 2021 | 44 | 2021 |
| Spondylodiscitis: evaluation of patients in a tertiary hospital S Kaya, S Ercan, S Kaya, U Aktas, K Kamasak, H Ozalp, K Cinar, ... The Journal of Infection in Developing Countries 8 (10), 1272-1276, 2014 | 41 | 2014 |
| Chronic myeloid leukemia patients who develop grade I/II pleural effusion under second-line dasatinib have better responses and outcomes than patients without pleural effusion AE Eskazan, D Eyice, EA Kurt, T Elverdi, FF Yalniz, A Salihoglu, MC Ar, ... Leukemia Research 38 (7), 781-787, 2014 | 39 | 2014 |
| Acute acalculous cholecystitis due to viral hepatitis A S Kaya, AE Eskazan, N Ay, B Baysal, MV Bahadir, A Onur, R Duymus Case reports in infectious diseases 2013, 2013 | 35 | 2013 |
| Diyarbakır Eğitim Araştırma Hastanesi sağlık çalışanlarında kesici delici alet yaralanmalarının değerlendirilmesi Ş Kaya, B Baysal, AE Eşkazan, H Çolak Viral Hepatit Dergisi 18 (3), 107-10, 2012 | 35 | 2012 |
| Dasatinib for the treatment of chronic myeloid leukemia: patient selection and special considerations D Keskin, S Sadri, AE Eskazan Drug design, development and therapy 10, 3355, 2016 | 34 | 2016 |
| Pleural and pericardial effusions in chronic myeloid leukemia patients receiving low-dose dasatinib therapy AE Eskazan, T Soysal, S Ongoren, E Gulturk, B Ferhanoglu, Y Aydin Haematologica 96 (3), e15, 2011 | 32 | 2011 |
| New drugs approved for acute myeloid leukaemia in 2018 S Kucukyurt, AE Eskazan British Journal of Clinical Pharmacology 85 (12), 2689-2693, 2019 | 30 | 2019 |
| Caplacizumab as an emerging treatment option for acquired thrombotic thrombocytopenic purpura T Elverdi, AE Eskazan Drug design, development and therapy 13, 1251, 2019 | 27 | 2019 |
| Third-line treatment with second-generation tyrosine kinase inhibitors (dasatinib or nilotinib) in patients with chronic myeloid leukemia after two prior TKIs: real-life data … S Ongoren, AE Eskazan, V Suzan, S Savci, I Erdogan Ozunal, S Berk, ... Hematology 23 (4), 212-220, 2018 | 26 | 2018 |
| First line treatment of chronic phase chronic myeloid leukaemia patients with the generic formulations of imatinib mesylate AE Eskazan, M Ayer, B Kantarcioglu, D Arica, N Demirel, D Aydin, ... British journal of haematology 167 (1), 139-141, 2014 | 26 | 2014 |
| Generics in chronic myeloid leukemia: current arguments for and against and the established evidence T Soysal, AE Eskazan, MC Ar Expert Review of Hematology 7 (6), 697-699, 2014 | 25 | 2014 |
| The efficacy of generic formulations of imatinib mesylate in the treatment of chronic myeloid leukemia AE Eskazan, T Elverdi, FF Yalniz, A Salihoglu, MC Ar, S Ongoren Aydin, ... Leukemia & Lymphoma 55 (12), 2935-2937, 2014 | 25 | 2014 |
| The impact of BCR‐ABL1 transcript type on tyrosine kinase inhibitor responses and outcomes in patients with chronic myeloid leukemia A Ercaliskan, AE Eskazan Cancer 124 (19), 3806-3818, 2018 | 24 | 2018 |
| Brucellar pericarditis: a report of four cases and review of the literature S Kaya, AE Eskazan, N Elaldi International Journal of Infectious Diseases 17 (6), e428-e432, 2013 | 24 | 2013 |
| Outcomes of chronic myeloid leukemia patients with early molecular response at 3 and 6 months: a comparative analysis of generic imatinib and glivec AE Eskazan, S Sadri, D Keskin, M Ayer, B Kantarcioglu, N Demirel, ... Clinical Lymphoma Myeloma and Leukemia 17 (12), 804-811, 2017 | 23 | 2017 |
